HONG KONG – South Korean biopharmaceutical company Samsung Bioepis Co. Ltd., based in Incheon, will expand into the Brazilian market with Brenzys (etanercept), having recently signed a marketing agreement with Brazil's Ministry of Health. The drug is now available through the country's public health system, Sistema Único de Saùde (SUS).

LONDON - More than half of the 216 newly approved drugs reviewed by Germany's health technology assessment (HTA) agency between 2011 and 2017 did not have evidence to show they provided benefit over the existing standard of care.